OBJECTIVE: To investigate the effect of three different tyrosine kinase inhibitors (TKIs) on the biodistribution of chimeric monoclonal antibody (mAb) cG250, which identifies carbonic anhydrase IX (CAIX), in nude mice bearing human renal cell carcinoma (RCC) xenografts. TKIs represent the best, but still suboptimal treatment for metastatic RCC (mRCC) and combined therapy or sequential therapy might be beneficial. CAIX is abundantly over expressed in RCC and clinical trials have shown abundant and specific tumour accumulation of cG250. Combining a TKI with mAb cG250, involved in a different effector mechanism, might lead to improved tumour responses and survival in patients with mRCC. MATERIALS AND METHODS: Nude mice bearing human RCC xenogr...
Item does not contain fulltextThe chimeric monoclonal antibody cG250 targets the G250 antigen, a tra...
Contains fulltext : 48341.pdf (publisher's version ) (Closed access)We have develo...
Background: There is a lack of biomarkers to predict outcome with targeted therapy in metastatic cle...
Monoclonal antibody G250 (mAbG250) recognizes a determinant on carbonic anhydrase IX (CAIX). CAIX is...
Item does not contain fulltextImmunotherapeutic targeting of G250/Carbonic anhydrase IX (CA-IX) repr...
Background: Carbonic anhydrase (CA) IX is a surface-expressed protein that is upregulated by the hyp...
Abstract Introduction: Monoclonal antibody (mAb) cG250 recognizes carbonic anhydrase IX (CAIX), over...
The carbonic anhydrase isoform IX (CAIX) enzyme is constitutively overexpressed in the vast majority...
Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive increase i...
A new approach in the treatment of clear cell renal carcinoma (ccRCC) is radioimmunotherapy (RIT) us...
Carbonic anhydrase IX (CAIX) is a tumor-associated antigen and marker of hypoxia that is overexpress...
Advances in the treatment of metastatic clear cell renal cell carcinoma (ccRCC) have led to improved...
A new approach in the treatment of clear cell renal carcinoma (ccRCC) is radioimmunotherapy (RIT) us...
In this study, we compared the tumor-targeting properties, therapeutic efficacy, and tolerability of...
Purpose: Antibody-drug conjugates and small-molecule-drug conjugates have been proposed as alternati...
Item does not contain fulltextThe chimeric monoclonal antibody cG250 targets the G250 antigen, a tra...
Contains fulltext : 48341.pdf (publisher's version ) (Closed access)We have develo...
Background: There is a lack of biomarkers to predict outcome with targeted therapy in metastatic cle...
Monoclonal antibody G250 (mAbG250) recognizes a determinant on carbonic anhydrase IX (CAIX). CAIX is...
Item does not contain fulltextImmunotherapeutic targeting of G250/Carbonic anhydrase IX (CA-IX) repr...
Background: Carbonic anhydrase (CA) IX is a surface-expressed protein that is upregulated by the hyp...
Abstract Introduction: Monoclonal antibody (mAb) cG250 recognizes carbonic anhydrase IX (CAIX), over...
The carbonic anhydrase isoform IX (CAIX) enzyme is constitutively overexpressed in the vast majority...
Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive increase i...
A new approach in the treatment of clear cell renal carcinoma (ccRCC) is radioimmunotherapy (RIT) us...
Carbonic anhydrase IX (CAIX) is a tumor-associated antigen and marker of hypoxia that is overexpress...
Advances in the treatment of metastatic clear cell renal cell carcinoma (ccRCC) have led to improved...
A new approach in the treatment of clear cell renal carcinoma (ccRCC) is radioimmunotherapy (RIT) us...
In this study, we compared the tumor-targeting properties, therapeutic efficacy, and tolerability of...
Purpose: Antibody-drug conjugates and small-molecule-drug conjugates have been proposed as alternati...
Item does not contain fulltextThe chimeric monoclonal antibody cG250 targets the G250 antigen, a tra...
Contains fulltext : 48341.pdf (publisher's version ) (Closed access)We have develo...
Background: There is a lack of biomarkers to predict outcome with targeted therapy in metastatic cle...